The aim of this study was to determine, quantitiatively, the production of nitric oxide (NO) in the nose and nasopharynx. Subjects were instructed to perform a Valsalva manoeuvre with their mouth open as gas was aspirated from a closely fitting nasal CPAP mask by a chemiluminescence analyser (Sievers 2708, Sievers Instrument Corp. Boulder, Colorado, U.S.A.). Room air was free to flow in through the mouth and out through the nose and hence to the analyser. The manoeuvre was continued until a smooth plateau of at least 20 seconds in duration was achieved on a chart recorder. The mean plateau concentrations were 176 (±39.6) parts per billion (ppb) for males and 135.8 (±24.4) ppb for females. The mean male production of NO was 15.8 nanomollmin which was significantly different from that of females of 12.5 nanomollmin (Mann-Whitney U Test: P<0.01). By measuring the concentration of NO in gas aspirated from the nose during Valsalva manoeuvre, we excluded the respiratory tract below the glottis from our sampling and as such results represent the portion of NO produced in the nose and nasopharynx. These findings suggest that nasally produced NO is produced in sufficient quantities to act as a continuous pulmonary vasodilator, being inspired preferentially into areas of greatest ventilation, thus perhaps acting to continually match ventilation to perfusion.
Nitric oxide (NO) is produced by various mammalian cell types, including neurones 1,2, endothelial cells]", and macrophages 5 ,6 and acts variously as an intercellular messenger and cytotoxic agent. Particular interest has focused on its role in modulating pulmonary vascular tone in both health'8 and disease 9 . '2 and its therapeutic role in disease states such as adult respiratory distress syndrome (ARDS)" and pulmonary hypertension 14·17 • Early studies demonstrating an improvement in arterial oxygen tension and a decrease in calculated intrapulmonary shunt utilized inhaled concentrations of NO of 20-80 parts per million (ppm)"''', but more recent work has demonstrated that much lower doses from 50-250 ppb are very likely effective '9 . 21 • Several researchers have demonstrated the release of nitric oxide from the respiratory tract of rabbits, guinea pigs 22 and humans 22 ,2J. However the site of the release has not been clearly elucidated. Because NO diffuses so rapidly and binds to haemoglobin so rapidly and avidly it is unlikely that much of the NO detected in exhaled breath originates from alveoli, alveolar ducts or respiratory bronchioles.
We have developed a technique that demonstrates that nitric oxide is released from the nose and perhaps the nasopharynx, and with this technique have documented the production of 15 (± 3) nanomollmin in healthy adult males and 12 (±2.5) nanomollmin in healthy females. The volume of NO produced may account for most, if not all the NO documented in previously reported human studies.
PATIENTS AND METHODS
Our institution's Ethics Review Committee approved the study. Twenty-one healthy volunteers with no current or past history of airway disease, especially asthma or hay fever, were enrolled. Each subject was instructed to perform a Valsalva manoeuvre with their mouth open, and a closely fitting nasal CPAP mask was applied over the nose. Air was aspirated from the mask at a flow rate of 2000 mllminute by a vacuum pump attached to a NO chemiluminescence analyser (Sievers 270B, Sievers Instrument Corp., Boulder, Colorado, U.S.A.). Room air was free to flow in through the mouth and out through the nose and thence to the analyser. Some subjects were unable to maintain a patent upper airway with this technique and instead had gas aspirated from a mouth-piece, with their nose open to air, whilst performing a Valsalva manoeuvre. A typical trace obtained is shown in Before and after performing patient measurements, the analyser was calibrated with a certified mixture of 1.0 ppm NO in N 2 • The flow rate through the analyser was set at 2000 mllminute by connecting to a calibrated air flowmeter, allowing the machine to aspirate air and adjusting the needle valve. The flow rate was checked after each set of measurements. This high rate was chosen to minimize any inaccuracies due to aspiration of the deadspace within the nasal mask and any change in volume of the upper airway during aspiration.
Since the concentration of NO aspirated and the flow rate were known it was possible to estimate the production of NO in terms of nanomol per minute, using the ideal gas laws.
RESULTS
lWenty-five subjects were enrolled; four were excluded because of their inability to perform the test as described, whilst maintaining a patent upper airway. Thus 21 subjects (13 males and eight females) were studied. Demographic data and results are tabulated in Table 1 . Mean plateau concentrations at 2000 mllmin aspirate flow rate were 176 (±39.6) (males) and 135.8 (± 24.4) parts per billion (females). Male mean production of 15.8 nanomollmin was different from female mean production of 12.5 nanomollmin (Mann- Whitney U Test; P<O.OI). Eleven out of the thirteen male subjects had measured production between 13 and 18 nanomollmin.
DISCUSSION
By measuring the NO concentration in air aspirated through the nose, during an open-mouth Valsalva manoeuvre, we excluded the respiratory tract below the glottis from our sampling. Thus our results demonstrate the production of NO by the upper airway in healthy awake volunteers.
The measured NO concentration is greater than that previously measured from the human respiratory tract. Previous studies 23 . 24 may have only documented entrainment from the nose during exhalation whilst a large proportion of inhaled NO was probably absorbed by haemoglobin within the pulmonary circulation.
Two previous studies have demonstrated high peak NO concentrations in human exhaled breath. However the paper by Persson 23 demonstrated a high peak after a 15 second breath-hold at the very initiation of exhalation suggesting diffusion of NO from some upper part of the airway. Another study by this group24 also demonstrated high initial NO concentrations especially after breath-holding. The measured NO deadspace appeared to be siinilar to that of COx. However during quiet breathing the concentration of exhaled NO measured was much lower than we found within the nose; it would be difficult to be certain that entrainment from the nose did not begin just after the commencement of expiration.
The work of Kharitonov et al 26 demonstrated a rising NO concentration with a "slow" exhaled breath over 30 to 75 seconds. Expiratory flows were not reported. It is unlikely that subjects could smoothly exhale over such a long period and therefore the peak seen may have represented active aspiration by the analyser from the upper airway, and most likely the nose and perhaps the nasopharynx. This group also noted that the same concentration of NO in exhaled breath was measured after inhalation of 800 ppb NO, implying that there is complete clearance of inhaled NO by the lungs, most probably due to adsorption by haemoglobin. It is therefore unlikely that any NO produced in the alveoli, alveolar ducts, or respiratory bronchioles would be detectable in exhaled breath, especially after prolonged breath-hold or very slow exhalation. Two studies 23 . 25 reported higher measured levels in asthmatic patients. In one study25, four volunteers inhaled nebulized NMMA, a NO synthetase inhibitor, with a reduction in measured NO. Some nebulized NMMA undoubtedly reached the nasal epithelium. If NO is produced in the nose the effect of allergic rhinitis on its production I. R. JENKINS, D. LANGLOIS deserves investigation, as does the effect of NO synthetase inhibitors on this disease state. One other group26 has demonstrated a higher concentration of NO in inspired versus expired air in the nasopharynx and trachea, during ventilation of healthy volunteers through a nasal mask, but flow rates were not reported, nor were the changes in concentration during the inspiratory and expiratory flow. Thus the rate of nasal production could not be estimated, nor could their calculation that about 50070 of the inspired NO is absorbed be substantiated. Our own published observations suggest that nearly all inspired NO is absorbed during a five-second breath-hold. The diffusion coefficient for NO, DLNO, is about five times greater than that of carbon monoxide 27 .
Of note, Gerlach et aP6 demonstrated that smokers have lower concentrations of NO in the nasopharynx, implying lower production. Persson also demonstrated lower exhaled levels in smokers 24 . The effects, both chronic and acute, of smoking on nasal NO production need to be more fully elucidated.
The many functions of the nose as part of the respiratory tree, other than NO production, have recently been the subject of a commentary2S. The physiological role of nasally produced NO has yet to be elucidated but it is tempting to speculate that it acts as a continuous pulmonary vasodilator and in being inspired most into areas of greatest ventilation, helps to continually match perfusion to ventilation. The quantity produced nasally in healthy awake adults, when diluted in the minute volume, would result in a similar delivery of NO to the lower respiratory tract as delivered in the studies of Gerlach et aP9,21 demonstrating a therapeutic effect of very low concentrations (10-200 ppb) of NO in ventilated patients with ARDS. Processes such as mouth-breathing and snoring and interventions such as tracheal intubation or tracheostomy prevent endogenously produced nitric oxide from reaching the lower respiratory tract.
The interrelation between conditions such as smoking or sleep apnoea, the production of NO and pulmonary hypertension require further study. It is likely that asthmatics have a higher upper airway (including nasal mucosal) production than the normal population, given the results of previous studies.
